303 related articles for article (PubMed ID: 8423042)
21. Effects of a 7-day treatment with midodrine in non-azotemic cirrhotic patients with and without ascites.
Kalambokis G; Fotopoulos A; Economou M; Pappas K; Tsianos EV
J Hepatol; 2007 Feb; 46(2):213-21. PubMed ID: 17156883
[TBL] [Abstract][Full Text] [Related]
22. Natriuretic effect of an adenosine-1 receptor antagonist in cirrhotic patients with ascites.
Stanley AJ; Forrest EH; Dabos K; Bouchier IA; Hayes PC
Gastroenterology; 1998 Aug; 115(2):406-11. PubMed ID: 9679046
[TBL] [Abstract][Full Text] [Related]
23. Renal effects of treatment with diuretics, octreotide or both, in non-azotemic cirrhotic patients with ascites.
Kalambokis G; Economou M; Fotopoulos A; Bokharhii JA; Katsaraki A; Tsianos EV
Nephrol Dial Transplant; 2005 Aug; 20(8):1623-9. PubMed ID: 15886218
[TBL] [Abstract][Full Text] [Related]
24. Effect of low-dose dopamine on kidney function and vasoactive hormones in pediatric patients with advanced renal failure.
Tulassay T; Rascher W; Schärer K
Clin Nephrol; 1987 Jul; 28(1):22-7. PubMed ID: 3621687
[TBL] [Abstract][Full Text] [Related]
25. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome.
Wong F; Pantea L; Sniderman K
Hepatology; 2004 Jul; 40(1):55-64. PubMed ID: 15239086
[TBL] [Abstract][Full Text] [Related]
26. Hemodynamic, renal, and endocrine effects of acute inhibition of nitric oxide synthase in compensated cirrhosis.
La Villa G; Barletta G; Pantaleo P; Del Bene R; Vizzutti F; Vecchiarino S; Masini E; Perfetto F; Tarquini R; Gentilini P; Laffi G
Hepatology; 2001 Jul; 34(1):19-27. PubMed ID: 11431729
[TBL] [Abstract][Full Text] [Related]
27. Inappropriately low angiotensin II generation: a factor determining reduced kidney function and survival in patients with decompensated cirrhosis.
Sansoé G; Silvano S; Mengozzi G; Todros L; Smedile A; Touscoz G; Rosina F; Rizzetto M
J Hepatol; 2004 Mar; 40(3):417-23. PubMed ID: 15123355
[TBL] [Abstract][Full Text] [Related]
28. [Aldosterone and renin in liver cirrhosis with ascites].
Vetter H; Vetter W; Beckerhoff R; Glänzer K; Furrer J; Hahn C; Kolloch R; Krück F; Kutz K; Siegenthaler W; Witassek F
Schweiz Med Wochenschr; 1977 Dec; 107(48):1755-9. PubMed ID: 929137
[TBL] [Abstract][Full Text] [Related]
29. [Renal effects of the chronic inhibition of nitric oxide synthesis in cirrhotic rats with ascites].
Ortiz MC; Fortepiani LA; Martínez-Salgado C; Eleno N; Atucha NM; López-Novoa JM; García-Estañ J
Nefrologia; 2001; 21(6):556-64. PubMed ID: 11881425
[TBL] [Abstract][Full Text] [Related]
30. Increased activity of guanosine 3'-5'-cyclic monophosphate phosphodiesterase in the renal tissue of cirrhotic rats with ascites.
Angeli P; Jiménez W; Veggian R; Fasolato S; Volpin R; MacHenzie HS; Craighero R; Libera VD; Sticca A; Arroyo V; Gatta A
Hepatology; 2000 Feb; 31(2):304-10. PubMed ID: 10655250
[TBL] [Abstract][Full Text] [Related]
31. Studies of renin and aldosterone in cirrhotic patients with ascites.
Rosoff L; Zia P; Reynolds T; Horton R
Gastroenterology; 1975 Sep; 69(3):698-705. PubMed ID: 1158087
[TBL] [Abstract][Full Text] [Related]
32. Effects of somatostatin on renal function in cirrhosis.
Ginès A; Salmerón JM; Ginès P; Jiménez W; Saló J; Piera C; Clària J; Rivera F; Arroyo V; Rodés J
Gastroenterology; 1992 Dec; 103(6):1868-74. PubMed ID: 1360435
[TBL] [Abstract][Full Text] [Related]
33. Long-term renal sodium handling in patients with cirrhosis treated with transjugular intrahepatic portosystemic shunts for refractory ascites.
Wong W; Liu P; Blendis L; Wong F
Am J Med; 1999 Mar; 106(3):315-22. PubMed ID: 10190381
[TBL] [Abstract][Full Text] [Related]
34. Improved renal function and inhibition of renin and aldosterone secretion following peritoneovenous (LeVeen) shunt.
Berkowitz HD; Mullen JL; Miller LD; Rosato EF
Surgery; 1978 Jul; 84(1):120-6. PubMed ID: 663820
[TBL] [Abstract][Full Text] [Related]
35. Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites.
Clària J; Kent JD; López-Parra M; Escolar G; Ruiz-Del-Arbol L; Ginès P; Jiménez W; Vucelic B; Arroyo V
Hepatology; 2005 Mar; 41(3):579-87. PubMed ID: 15723448
[TBL] [Abstract][Full Text] [Related]
36. Functional role of endogenous adenosine in human chronic renal disease.
Balakrishnan VS; Coles GA; Williams JD
Exp Nephrol; 1996; 4(1):26-36. PubMed ID: 8788597
[TBL] [Abstract][Full Text] [Related]
37. The renal and hemodynamic effects of the peritoneovenous shunt for intractable hepatic ascites.
Blendis LM; Greig PD; Langer B; Baigrie RS; Ruse J; Taylor BR
Gastroenterology; 1979 Aug; 77(2):250-7. PubMed ID: 447039
[TBL] [Abstract][Full Text] [Related]
38. [The renin-angiotensin-aldosterone system in liver cirrhosis].
Giudici Cipriani A; Folco U; Colombo P; Menardo G; Cattana A; Barbetti V; Rembado R; Marenco G
Minerva Med; 1990; 81(1-2):45-53. PubMed ID: 2314615
[TBL] [Abstract][Full Text] [Related]
39. Renal insensitivity to atrial natriuretic peptide in patients with cirrhosis and ascites. Effect of increasing systemic arterial pressure.
Ginès P; Titó L; Arroyo V; Llach J; Salmerón JM; Ginès A; Jiménez W; Badalamenti S; Rivera F; Rodés J
Gastroenterology; 1992 Jan; 102(1):280-6. PubMed ID: 1290472
[TBL] [Abstract][Full Text] [Related]
40. Urocortin 2 inhibits furosemide-induced activation of renin and enhances renal function and diuretic responsiveness in experimental heart failure.
Rademaker MT; Charles CJ; Nicholls MG; Richards AM
Circ Heart Fail; 2009 Nov; 2(6):532-40. PubMed ID: 19919977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
